ASK Capital Investment Managers LLC Buys 21,800 Shares of AbbVie Inc. $ABBV

ASK Capital Investment Managers LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 21,800 shares of the company’s stock, valued at approximately $5,703,000. AbbVie accounts for 6.3% of ASK Capital Investment Managers LLC’s holdings, making the stock its 2nd largest position.

A number of other large investors have also made changes to their positions in ABBV. XY Planning Network Inc. grew its stake in AbbVie by 33.4% in the third quarter. XY Planning Network Inc. now owns 1,846 shares of the company’s stock valued at $483,000 after acquiring an additional 462 shares during the period. Define Financial LLC acquired a new stake in shares of AbbVie during the third quarter worth about $237,000. ProCore Advisors LLC acquired a new stake in shares of AbbVie during the third quarter worth about $205,000. Salem Investment Counselors Inc. lifted its holdings in shares of AbbVie by 0.9% during the 3rd quarter. Salem Investment Counselors Inc. now owns 133,470 shares of the company’s stock valued at $34,914,000 after purchasing an additional 1,148 shares in the last quarter. Finally, Signal Advisors Wealth LLC grew its position in shares of AbbVie by 16.0% in the 3rd quarter. Signal Advisors Wealth LLC now owns 26,598 shares of the company’s stock valued at $6,958,000 after purchasing an additional 3,660 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on ABBV shares. Rothschild & Co Redburn raised their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and increased their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. HSBC raised their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Stock Down 2.2%

NYSE ABBV opened at $274.82 on Wednesday. The firm’s 50 day moving average is $260.41 and its 200-day moving average is $237.87. The company has a market capitalization of $485.55 billion, a PE ratio of 77.63, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $283.43.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 13.95 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. AbbVie’s payout ratio is 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential Q3 revenue beat: RBC expects AbbVie to exceed third-quarter revenue estimates, driven by continued momentum for immunology drugs Skyrizi and Rinvoq, as well as psychiatric medicine Vraylar. This supports expectations that newer products can offset Humira’s loss of exclusivity. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could strengthen Skyrizi’s position in a major growth market and expand AbbVie’s immunology opportunity. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and analyst support: Recent Crohn’s disease data for Skyrizi and Rinvoq, cancer-related regulatory milestones for Temab-A, and early metabolic-treatment data are improving the outlook for AbbVie’s post-Humira growth. RBC reaffirmed its “Outperform” rating, although its target implies only limited additional upside. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Neutral Sentiment: Strategic expansion: AbbVie’s acquisition of Apogee and related leadership moves highlight the company’s effort to replenish its pipeline through business development, but the long-term financial impact remains uncertain. Biotech Builder Paragon Imports Apogee’s Top Brass After AbbVie Buyout
• Negative Sentiment: Valuation and execution risks: At a high earnings multiple near its recent peak, ABBV may be vulnerable to profit-taking even with positive clinical news. Investors also remain concerned about Humira’s ongoing sales erosion, increasing immunology competition, and whether Skyrizi and Rinvoq can sustain their rapid growth.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.